Dexamethasone intraocular suspension 9% (Dexycu, EyePoint Pharmaceuticals) was launched in March 2019. Its advantages make it a natural choice to routinely replace topical corticosteroid drops in all Medicare cataract surgery patients.
Reviewed by Eric D. Donnenfeld, MD
Approved by the FDA last year, dexamethasone intraocular suspension 9% (Dexycu, EyePoint Pharmaceuticals) was officially launched in March. As an investigator in premarketing clinical trials, Eric D. Donnenfeld, MD, began using the novel sustained-release corticosteroid three years ago.
Based on his experience and the advantages of the intraocular product, Dr. Donnenfeld said he is now using it routinely in all cataract surgery cases involving Medicare patients.
“Drug delivery for medications used in cataract surgery is changing dramatically, and dexamethasone intraocular suspension is an exciting advance that overcomes the limitations of topically administered drops,” said Dr. Donnenfeld, clinical professor of ophthalmology, New York University Langone Medical Center, New York, NY, and founding partner, Ophthalmic Consultants of Long Island and Connecticut, Garden City, NY.
“It puts the surgeon in charge and takes the responsibility of the corticosteroid out of the hands of patients who may be unreliable or unable to administer their medication,” he said. “Furthermore, it avoids the potential ocular surface toxicity of topical medications and their cost.”
The dexamethasone intraocular suspension has been granted pass-through status and reimbursement by the Centers for Medicare and Medicaid Services, Dr. Donnenfeld noted. As a result, dexamethasone intraocular suspension is provided at no cost to the surgery center, the surgeon, or Medicare patients with coinsurance, who represent about 90% of the Medicare population.
In the few months since the intraocular corticosteroid became commercially available, Dr. Donnenfeld said that he has used it with excellent safety and efficacy in about 100 eyes that underwent cataract surgery, including some complex cases.
Eric D. Donnenfeld, MD
E: [email protected]
Dr. Donnenfeld is a consultant to EyePoint Pharmaceuticals and other companies marketing and developing products for treating inflammation after ophthalmic surgery.